

Francesco Negro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9118590/publications.pdf>

Version: 2024-02-01

159
papers

16,527
citations

30070

54
h-index

15732

125
g-index

175
all docs

175
docs citations

175
times ranked

15931
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
2	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018, 69, 461-511.	3.7	1,489
3	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.7	1,157
4	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. <i>Gastroenterology</i> , 2010, 138, 1338-1345.e7.	1.3	1,056
5	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020, 73, 1170-1218.	3.7	671
6	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7408-7413.	7.1	651
7	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.	4.4	559
8	Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. <i>Journal of Hepatology</i> , 2000, 33, 106-115.	3.7	532
9	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2006, 130, 1636-1642.	1.3	517
10	Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. <i>Journal of Hepatology</i> , 2018, 69, 718-735.	3.7	474
11	Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. <i>Medicine (United States)</i> , 2012, 91, 319-327.	1.0	441
12	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	3.9	333
13	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. <i>Gastroenterology</i> , 2015, 149, 1345-1360.	1.3	306
14	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 51, 655-666.	3.7	247
15	Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress. <i>Journal of Virology</i> , 2007, 81, 8122-8130.	3.4	240
16	The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. <i>Hepatology</i> , 2007, 45, 1164-1171.	7.3	214
17	The hepatitis delta virus: Replication and pathogenesis. <i>Journal of Hepatology</i> , 2016, 64, S102-S116.	3.7	212
18	Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. <i>Journal of Hepatology</i> , 2008, 48, 28-34.	3.7	177

#	ARTICLE	IF	CITATIONS
19	Abnormalities of lipid metabolism in hepatitis C virus infection. <i>Gut</i> , 2010, 59, 1279-1287.	12.1	157
20	An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. <i>Journal of Hepatology</i> , 2005, 42, 744-751.	3.7	155
21	The interaction of metabolic factors with HCV infection: Does it matter?. <i>Journal of Hepatology</i> , 2012, 56, S56-S65.	3.7	152
22	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	3.7	143
23	Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. <i>Liver International</i> , 2009, 29, 26-37.	3.9	142
24	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. <i>Gastroenterology</i> , 2012, 143, 1244-1252.e12.	1.3	142
25	Hepatitis C virus and type 2 diabetes. <i>World Journal of Gastroenterology</i> , 2009, 15, 1537.	3.3	140
26	Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. <i>Journal of Hepatology</i> , 2014, 61, S69-S78.	3.7	139
27	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. <i>Hepatology</i> , 2012, 55, 384-394.	7.3	138
28	Mechanisms and significance of liver steatosis in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2006, 12, 6756.	3.3	136
29	The global health burden of hepatitis C virus infection. <i>Liver International</i> , 2011, 31, 1-3.	3.9	121
30	Reduced IFN γ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. <i>Nature Communications</i> , 2014, 5, 5699.	12.8	117
31	Is genotype 3 of the hepatitis C virus the new villain?. <i>Hepatology</i> , 2014, 59, 2403-2412.	7.3	116
32	Hepatitis D virus: an update. <i>Liver International</i> , 2011, 31, 7-21.	3.9	108
33	Viral genotype-specific role of PNPLA3 , PPARC , MTP, and IL28B in hepatitis C virus-associated steatosis. <i>Journal of Hepatology</i> , 2011, 55, 529-535.	3.7	98
34	Hepatitis D Virus Coinfection and Superinfection. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a021550-a021550.	6.2	94
35	Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. <i>Journal of Hepatology</i> , 2020, 73, 533-539.	3.7	94
36	Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. <i>Journal of Hepatology</i> , 2008, 49, 429-440.	3.7	91

#	ARTICLE	IF	CITATIONS
37	Hepatitis delta virus inhibits alpha interferon signaling. <i>Hepatology</i> , 2009, 49, 398-406.	7.3	88
38	Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. <i>Scientific Reports</i> , 2016, 6, 31777.	3.3	81
39	A review on hepatitis D: From virology to new therapies. <i>Journal of Advanced Research</i> , 2019, 17, 3-15.	9.5	78
40	Natural history of NASH and HCC. <i>Liver International</i> , 2020, 40, 72-76.	3.9	77
41	Pioglitazone in chronic hepatitis C not responding to pegylated interferon- α and ribavirin. <i>Journal of Hepatology</i> , 2008, 49, 295-298.	3.7	76
42	Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. <i>Hepatology</i> , 2008, 48, 799-807.	7.3	74
43	Epidemiology of hepatitis C in Europe. <i>Digestive and Liver Disease</i> , 2014, 46, S158-S164.	0.9	70
44	Evidence for replication of hepatitis delta virus RNA in hepatocyte nuclei after in vivo infection. <i>Virology</i> , 1988, 167, 274-278.	2.4	67
45	Chronic HDV (hepatitis delta virus) hepatitis. <i>Journal of Hepatology</i> , 1988, 6, 8-14.	3.7	66
46	Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. <i>Hepatology</i> , 2011, 54, 38-49.	7.3	66
47	Expression of liver steatosis in hepatitis C virus infection and pattern of response to α -interferon. <i>Journal of Hepatology</i> , 2001, 35, 307.	3.7	63
48	Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS). <i>International Journal of Epidemiology</i> , 2007, 36, 731-737.	1.9	63
49	Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?. <i>Swiss Medical Weekly</i> , 2020, 150, w20249.	1.6	63
50	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 1112-1121.	3.7	62
51	Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse transcriptase polymerase chain reaction. <i>Hepatology</i> , 1999, 29, 536-542.	7.3	61
52	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). <i>Gastroenterology</i> , 2007, 133, 1132-1143.	1.3	57
53	Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. <i>Journal of Medical Virology</i> , 2000, 60, 21-27.	5.0	56
54	Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. <i>Journal of Hepatology</i> , 1998, 29, 1-11.	3.7	54

#	ARTICLE	IF	CITATIONS
55	The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. <i>Journal of Hepatology</i> , 2010, 52, 635-643.	3.7	54
56	NAFLD and MAFLD as emerging causes of HCC: A populational study. <i>JHEP Reports</i> , 2021, 3, 100231.	4.9	54
57	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. <i>Hepatology</i> , 2002, 36, 1446-1452.	7.3	53
58	Insulin resistance and HCV: Will new knowledge modify clinical management?. <i>Journal of Hepatology</i> , 2006, 45, 514-519.	3.7	52
59	Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1295.	4.1	48
60	Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	7.3	48
61	Adverse effects of drugs in the treatment of viral hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 183-192.	2.4	47
62	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1619-1628.	4.4	47
63	Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 724-735.	8.1	47
64	Current understanding of insulin resistance in hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 503-516.	3.0	44
65	Hepatitis C Virus Infection: Molecular Pathways to Steatosis, Insulin Resistance and Oxidative Stress. <i>Viruses</i> , 2009, 1, 126-143.	3.3	40
66	Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance. <i>Nature Communications</i> , 2017, 8, 1820.	12.8	40
67	Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. <i>Journal of Advanced Research</i> , 2017, 8, 149-159.	9.5	39
68	The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172.	3.9	38
69	PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. <i>Journal of Hepatology</i> , 2013, 59, 420-426.	3.7	37
70	A systematic review and meta-analysis of HCV clearance. <i>Liver International</i> , 2017, 37, 1431-1445.	3.9	37
71	Hepatitis C Virus-Induced Steatosis: An Overview. <i>Digestive Diseases</i> , 2010, 28, 294-299.	1.9	35
72	Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e. <i>Journal of General Virology</i> , 2014, 95, 1677-1688.	2.9	34

#	ARTICLE	IF	CITATIONS
73	Devil hepatitis D: an orphan disease or largely underdiagnosed?. <i>Gut</i> , 2019, 68, 381-382.	12.1	34
74	The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. <i>Liver International</i> , 2011, 31, 66-74.	3.9	32
75	Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. <i>Liver International</i> , 2008, 28, 370-376.	3.9	31
76	HCV Infection and Metabolic Syndrome: Which Is the Chicken and Which Is the Egg?. <i>Gastroenterology</i> , 2012, 142, 1288-1292.	1.3	31
77	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. <i>Journal of Hepatology</i> , 2016, 64, 29-36.	3.7	30
78	Endpoints and New Options for Treatment of Chronic Hepatitis D. <i>Hepatology</i> , 2021, 74, 3479-3485.	7.3	26
79	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. <i>PLoS ONE</i> , 2015, 10, e0125214.	2.5	25
80	Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein. <i>Liver International</i> , 2019, 39, 1226-1236.	3.9	24
81	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	3.9	24
82	IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. <i>Journal of Medical Virology</i> , 1998, 56, 224-229.	5.0	23
83	Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients. , 1999, 59, 277-280.		23
84	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis C. <i>Clinics in Liver Disease</i> , 2014, 18, 147-156.	2.1	23
85	Cardiovascular Manifestations of Hepatitis C Virus. <i>Clinics in Liver Disease</i> , 2017, 21, 465-473.	2.1	23
86	The comprehensive outcomes of hepatitis C virus infection: A multifaceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-14.	2.0	23
87	HCV 3a Core Protein Increases Lipid Droplet Cholesteryl Ester Content via a Mechanism Dependent on Sphingolipid Biosynthesis. <i>PLoS ONE</i> , 2014, 9, e115309.	2.5	23
88	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020, 40, 778-786.	3.9	22
89	Residual risk of liver disease after hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2021, 74, 952-963.	3.7	22
90	Mechanisms of hepatitis C virus-related insulin resistance. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 358-363.	1.5	21

#	ARTICLE	IF	CITATIONS
91	Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: Comparison between different genotypes and core protein sequence analysis. <i>Journal of Medical Virology</i> , 2011, 83, 1005-1015.	5.0	21
92	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.	7.3	21
93	Antigenic relevance of F protein in chronic hepatitis C virus infection. <i>Hepatology</i> , 2004, 40, 900-909.	7.3	20
94	Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. <i>PLoS ONE</i> , 2019, 14, e0217751.	2.5	20
95	Does the hepatitis C virus replicate in cells of the hematopoietic lineage?. <i>Hepatology</i> , 1998, 28, 261-264.	7.3	18
96	Acute valproate-associated microvesicular steatosis: could the [13C]methionine breath test be useful to assess liver mitochondrial function?. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2758-2761.	2.3	18
97	HCV causes systemic disorders that can be cured. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 77-78.	17.8	18
98	Primary Hepatic Diffuse Large B-Cell Lymphoma in a Patient with Chronic Hepatitis C. <i>American Journal of Surgical Pathology</i> , 1999, 23, 1124.	3.7	18
99	Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus. <i>Journal of Pathology</i> , 2002, 197, 617-623.	4.5	17
100	Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. <i>Antiviral Research</i> , 2018, 150, 9-14.	4.1	17
101	Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 204-209.	0.8	17
102	Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. <i>Cancers</i> , 2021, 13, 4983.	3.7	17
103	Ribavirin restores IFN α responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. <i>Gut</i> , 2016, 65, 672-682.	12.1	16
104	Drug Pricing Evolution in Hepatitis C. <i>PLoS ONE</i> , 2016, 11, e0157098.	2.5	16
105	Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis. <i>Antiviral Research</i> , 2001, 52, 161-171.	4.1	15
106	HDV Pathogenesis: Unravelling Ariadne's Thread. <i>Viruses</i> , 2021, 13, 778.	3.3	14
107	Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease. <i>World Journal of Hepatology</i> , 2018, 10, 73-81.	2.0	14
108	HCV disease burden and population segments in Switzerland. <i>Liver International</i> , 2022, 42, 330-339.	3.9	14

#	ARTICLE	IF	CITATIONS
109	Peroxisome Proliferator-Activated Receptors and Hepatitis C Virus-Induced Insulin Resistance. PPAR Research, 2009, 2009, 1-6.	2.4	13
110	Very Low Hepatitis C Viral Loads in Treatment-naïve Persons: Do They Compromise Hepatitis C Virus Antigen Testing?. Clinical Infectious Diseases, 2019, 70, 653-659.	5.8	13
111	Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis. Journal of Viral Hepatitis, 2019, 26, 236-245.	2.0	13
112	Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036921.	6.2	13
113	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PLoS ONE, 2018, 13, e0209374.	2.5	12
114	Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. JHEP Reports, 2021, 3, 100279.	4.9	12
115	Nonalcoholic fatty liver disease burden "Switzerland 2018"2030. Swiss Medical Weekly, 2019, 149, w20152.	1.6	12
116	Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 3735.	3.3	11
117	Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. Infectious Diseases and Therapy, 2021, 10, 2203-2222.	4.0	11
118	Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. Digestive and Liver Disease, 2012, 44, 419-425.	0.9	10
119	Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplant International, 2004, 17, 169-176.	1.6	9
120	Role of seipin in lipid droplet morphology and hepatitis C virus life cycle. Journal of General Virology, 2013, 94, 2208-2214.	2.9	9
121	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. PLoS ONE, 2016, 11, e0155464.	2.5	9
122	Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Medical Weekly, 2019, 149, w20026.	1.6	9
123	Extrahepatic manifestations in hepatitis C virus infection. Journal of Advanced Research, 2017, 8, 85-87.	9.5	8
124	Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein. PLoS ONE, 2016, 11, e0146000.	2.5	8
125	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Medical Weekly, 2015, 145, w14221.	1.6	8
126	Does telaprevir possess a direct antidiabetic effect?. Liver International, 2014, 34, 967-969.	3.9	7

#	ARTICLE	IF	CITATIONS
127	SARS-CoV-2 and liver damage: a possible pathogenetic link. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 322-324.	1.5	7
128	<i>BRIP1</i> coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. <i>Oncotarget</i> , 2017, 8, 62842-62857.	1.8	7
129	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. <i>Swiss Medical Weekly</i> , 2019, 149, w14694.	1.6	7
130	Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection. <i>Journal of Virological Methods</i> , 1996, 60, 179-182.	2.1	6
131	Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America. <i>Journal of Tropical Medicine</i> , 2018, 2018, 1-10.	1.7	6
132	Tolerogenic properties of liver macrophages in non-alcoholic steatohepatitis. <i>Liver International</i> , 2020, 40, 609-621.	3.9	6
133	All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa308.	0.9	6
134	A buyers' club to improve access to hepatitis C treatment for vulnerable populations. <i>Swiss Medical Weekly</i> , 2018, 148, w14649.	1.6	6
135	Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. <i>Liver International</i> , 2013, 33, 94-103.	3.9	5
136	A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen on fibrosis progression in chronic C hepatitis with or without liver transplantation. <i>Liver International</i> , 2016, 36, 1331-1339.	3.9	4
137	Nucleic acid polymers: much-needed hope for hepatitis D?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 841-842.	8.1	4
138	Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection. <i>Antiviral Therapy</i> , 2018, 23, 57-67.	1.0	4
139	Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. <i>PLoS ONE</i> , 2019, 14, e0218706.	2.5	4
140	Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. <i>Swiss Medical Weekly</i> , 2021, 151, w20399.	1.6	4
141	Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison. <i>Journal of Global Health</i> , 2018, 8, 020407.	2.7	4
142	Curbing hepatitis C virus spread in Egypt. <i>The Lancet Global Health</i> , 2014, 2, e495-e496.	6.3	3
143	Are statins a remedy for all seasons?. <i>Journal of Hepatology</i> , 2015, 62, 8-10.	3.7	3
144	The never-ending debate about conflict of interests'. <i>Liver International</i> , 2021, 41, 1443-1444.	3.9	3

#	ARTICLE	IF	CITATIONS
145	IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. <i>Journal of Medical Virology</i> , 1998, 56, 224-229.	5.0	3
146	Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. <i>Journal of Medical Virology</i> , 2000, 60, 21.	5.0	3
147	Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over. <i>Swiss Medical Weekly</i> , 2017, 147, w14570.	1.6	3
148	Steatosis in chronic hepatitis C: friend or foe?. <i>Liver International</i> , 2008, 28, 294-296.	3.9	2
149	Cause-effect relationship between the hepatitis C virus and insulin resistance at the time of direct antiviral therapy. <i>Gut</i> , 2010, 59, 1590-1591.	12.1	2
150	The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomes. <i>BMC Medical Education</i> , 2020, 20, 425.	2.4	2
151	Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis. <i>PeerJ</i> , 2021, 9, e11895.	2.0	2
152	Nonradioisotopic <I>In Situ</I> Hybridization for HDV RNA. , 2004, 95, 95-98.		0
153	Management of HCV Infection. , 2016, , 61-78.		0
154	The heavy burden of hepatitis D in Uzbekistan. <i>Liver International</i> , 2019, 39, 2034-2035.	3.9	0
155	IDDF2019-ABS-0212-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis. , 2019, , .		0
156	Update in Drug Development for Chronic HBV/HDV Infection. <i>Current Hepatology Reports</i> , 2019, 18, 522-530.	0.9	0
157	Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma"; <i>Journal of Hepatology</i> , 2020, 73, 1585-1586.	3.7	0
158	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <i>The Cochrane Library</i> , 2021, 2021, .	2.8	0
159	Scaling-up hepatitis C screening and treatment in Swiss outpatient psychiatric settings: A cost-effectiveness analysis. <i>JHEP Reports</i> , 2022, 4, 100464.	4.9	0